Sector Close Up: Pharmaceutical and Biotech Stocks – is Gene Therapy the Next Major Breakthrough in Cancer Treatment?

Point Roberts, WA, October 24, 2007 --(PR.com)-- Benda Pharmaceutical, Inc. (OTCBB: BPMA) is a China-based pharmaceutical company that has become recognized for its cancer gene therapy treatment Gendicine®, which represents the world’s first gene therapy medicine on the market for the treatment of cancer. Gendicine® has been used to treat more than 50 types of malignant tumors across 6,000 patients, including more than 1,800 foreigners. According to the Company, in clinical trials on 135 patients affected by head and neck tumors, 64% had their tumors eliminated after one month of Gendicine® treatment - a 340% increase in efficacy relative to traditional treatments.

Full Article:
investorideas.com/Companies/ViewDocument.asp?ID=5166

Showcase Pharmaceutical Company:
Benda Pharmaceutical Inc. (OTCBB: BPMA), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. For more info visit: investorideas.com/co/bpma
Compensation is disclosed in disclaimer

About InvestorIdeas.com
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, Middle East and Australia.

InvestorIdeas.com Disclaimer: InvestorIdeas.com/About/Disclaimer.asp.

For more information contact:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source: InvestorIdeas.com, Benda Pharmaceutical, Inc.

###